Low-dose glucocorticoid therapy in rheumatoid arthritis
Trèves, R.
Revue du Rhumatisme 62(10): 611-617
1995
ISSN/ISBN: 1169-8446 PMID: 8624668 Document Number: 441145
Document emailed within 1 workday
Related Documents
Cortet, B.; Flipo, R.M.; Blanckaert, F.; Duquesnoy, B.; Marchandise, X.; Delcambre, B. 1997: Evaluation of bone mineral density in patients with rheumatoid arthritis. Influence of disease activity and glucocorticoid therapy Revue du Rhumatisme 64(7-9): 451-458Lange, U.; Illgner, U.; Teichmann, J.; Schleenbecker, H. 2004: Skeletal benefit after one year of risedronate therapy in patients with rheumatoid arthritis and glucocorticoid-induced osteoporosis: a prospective study International Journal of Clinical Pharmacology Research 24(2-3): 33-38
van den Borne, B.E.; Landewé, R.B.; Goei The, H.S.; Rietveld, J.H.; Zwinderman, A.H.; Bruyn, G.A.; Breedveld, F.C.; Dijkmans, B.A. 1998: Combination therapy in recent onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine Journal of Rheumatology 25(8): 1493-1498
Satoh, M.; Ajmani, A.K. 1993: Acute exacerbation mimicking "pseudoseptic" arthritis in rheumatoid arthritis could be caused by abrupt discontinuation of glucocorticoid Journal of Rheumatology 20(8): 1441-1442
Leeb, B.; Dunky, A.; Ogris, E.; Wohanka, A.; Schenk, G.; Gaismayer, K.; Eberl, R. 1989: Methotrexate serum-level determinations during low-dose therapy of rheumatoid and psoriatic arthritis International Journal of Clinical Pharmacology Research 9(3): 209-215
Lange, U.; Boss, B.; Teichmann, J.; Stracke, H.; Neeck, G. 2000: Bone mineral density and biochemical markers of bone metabolism in late onset rheumatoid arthritis and polymyalgia rheumatica--a prospective study on the influence of glucocorticoid therapy Zeitschrift für Rheumatologie 59(Suppl 2): Ii/137-Ii/141
Townsend, H.B.; Saag, K.G. 2004: Glucocorticoid use in rheumatoid arthritis: benefits, mechanisms, and risks Clinical and Experimental Rheumatology 22(5 Suppl 35: S77-S82
Imbimbo, B.; Tuzi, T.; Porzio, F.; Schiavetti, L. 1984: Clinical equivalence of a new glucocorticoid, deflazacort and prednisone in rheumatoid arthritis and S.L.E. patients Advances in Experimental Medicine and Biology 171: 241-256
Davis, J.C.; Fessler, B.J.; Tassiulas, I.O.; McInnes, I.B.; Yarboro, C.H.; Pillemer, S.; Wilder, R.; Fleisher, T.A.; Klippel, J.H.; Boumpas, D.T. 1998: High dose versus low dose fludarabine in the treatment of patients with severe refractory rheumatoid arthritis Journal of Rheumatology 25(9): 1694-1704
Masi, A.T.; Chrousos, G.P.; Bornstein, S.R. 1999: Enigmas of adrenal androgen and glucocorticoid dissociation in premenopausal onset rheumatoid arthritis Journal of Rheumatology 26(2): 247-250
Eggert, M.; Klüter, A.; Rusch, D.; Schmidt, K.L.; Dotzlaw, H.; Schulz, M.; Pabst, W.; Böke, J.ör.; Renkawitz, R.; Neeck, G. 2002: Expression analysis of the glucocorticoid receptor and the nuclear factor-kB subunit p50 in lymphocytes from patients with rheumatoid arthritis Journal of Rheumatology 29(12): 2500-2506
Tomiyama, H.; Takara, I.; Tokumine, J.; Sugahara, K. 2004: Sivelestat sodium hydrate was effective for ARDS in a patient suffering from chronic rheumatoid arthritis with acute exacerbation after failing to respond to high dose steroid pulse therapy Masui. Japanese Journal of Anesthesiology 53(9): 1042-1046
Furst, D.E.; Schiff, M.H.; Fleischmann, R.M.; Strand, V.; Birbara, C.A.; Compagnone, D.; Fischkoff, S.A.; Chartash, E.K. 2003: Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) Journal of Rheumatology 30(12): 2563-2571
Menon, N.; Kothari, S.Y.; Gogna, A.; Sharma, R. 2014: Comparison of intra-articular glucocorticoid injections with DMARDs versus DMARDs alone in rheumatoid arthritis Journal of the Association of Physicians of India 62(8): 673-676
Suzuki, Y.; Wakabayashi, T. 2015: Management of osteoporosis associated with rheumatoid arthritis and glucocorticoid-induced osteoporosis Clinical Calcium 25(12): 1825-1834
Luftschein, S.; Bienenstock, H.; Varady, J.C.; Stitt, F.W. 1979: Increasing dose of naproxen in rheumatoid arthritis: use with and without corticosteroids Journal of Rheumatology 6(4): 397-404
Patel, D.A.; Kristensen, P.L.; Pedersen-Bjergaard, U.; Schultz, H.H. 2018: Glucocorticoid-induced diabetes and risk factors during high-dose therapy Ugeskrift for Laeger 180(18)
Finkelstein, A.E.; Roisman, F.R.; Batista, V.; de Nudelman, F.G.; de Titto, E.H.; Mizraji, M.; Walz, D.T. 1980: Oral chrysotherapy in rheumatoid arthritis: minimum effective dose Journal of Rheumatology 7(2): 160-168
Van Herwaarden, N.; Herfkens-Hol, S.; van der Maas, A.; van den Bemt, B.J.F.; van Vollenhoven, R.F.; Bijlsma, J.W.J.; den Broeder, A.A. 2014: Dose reduction of tocilizumab in rheumatoid arthritis patients with low disease activity Clinical and Experimental Rheumatology 32(3): 390-394
Champion, G.D.; Cairns, D.R.; Bieri, D.; Adena, M.A.; Browne, C.D.; Cohen, M.L.; Day, R.O.; Edmonds, J.P.; Graham, G.G.; de Jager, J. 1988: Dose response studies and longterm evaluation of auranofin in rheumatoid arthritis Journal of Rheumatology 15(1): 28-34